Exploring a new way to enhance vaccine effectiveness using fungal components
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
This study is exploring a new way to make vaccines work better by using special ingredients from fungi to help your body produce stronger defenses against the SARS-CoV-2 virus, which could lead to more effective and longer-lasting protection for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10904880 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve vaccine responses by using fungal mannans as adjuvants. Adjuvants are substances that enhance the body's immune response to vaccines, and this study focuses on how these fungal components can activate specific immune receptors to boost antibody production against the SARS-CoV-2 virus. By testing a new formulation that combines these fungal ligands with traditional adjuvants, the research aims to create more effective vaccines that provide longer-lasting protection. Patients may benefit from improved vaccine efficacy and broader immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are receiving or considering vaccination against COVID-19.
Not a fit: Patients who are not eligible for vaccination or those with contraindications to vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against COVID-19 and potentially other infectious diseases.
How similar studies have performed: Other research has shown promise in using novel adjuvants to enhance vaccine responses, indicating that this approach could be a significant advancement in vaccine development.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Zanoni, Ivan — Boston Children's Hospital
- Study coordinator: Zanoni, Ivan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.